Defymed enters partnership with Semma Therapeutics

Posted on December 13, 2016

Strasbourg, December 12, 2016 - Defymed announces a strategic collaboration with Semma Therapeutics, an American biotechnology company specialising in the development of cell therapies for the treatment of diabetes, with the goal of developing of an innovative solution for treating type-1 diabetes. The collaboration is aimed at pre-clinical validation of the MAILPAN® bio-artificial pancreas, in combination with
Read full post »